百诚医药(301096.SZ)发布前三季度业绩，归母净利润612.42万元，下降95.68%

Core Insights - The company reported a significant decline in revenue and net profit for the first three quarters of 2025, indicating financial challenges ahead [1] Financial Performance - The company's operating revenue for the first three quarters was 510 million yuan, representing a year-on-year decrease of 29.33% [1] - The net profit attributable to shareholders was 6.1242 million yuan, down 95.68% compared to the previous year [1] - The net loss attributable to shareholders, after excluding non-recurring gains and losses, was 13.9173 million yuan [1] - Basic earnings per share were reported at 0.06 yuan [1]